(Total Views: 420)
Posted On: 02/27/2020 7:49:09 PM
Post# of 149003
Well, maybe now we know why GILD hasn’t gone after us aggressively enough.
Hope I’m wrong but this Could be trouble. Forty Seven partnering with GILD becomes a massive, well funded competitor in cancer - with a novel monoclonal antibody treatment.
Obviously there are other high quality competitors chasing the same goal - and these guys seem light years ahead in terms of money, connections, etc.
Hope I’m wrong but this Could be trouble. Forty Seven partnering with GILD becomes a massive, well funded competitor in cancer - with a novel monoclonal antibody treatment.
Obviously there are other high quality competitors chasing the same goal - and these guys seem light years ahead in terms of money, connections, etc.
(1)
(0)Scroll down for more posts ▼
